Sign in

    Arthur He

    Senior Equity Analyst at H.C. Wainwright & Co.

    Arthur He is a Senior Equity Analyst at H.C. Wainwright & Co., specializing in the biotechnology and therapeutics sectors with coverage on companies such as LAVA Therapeutics, Aurinia Pharmaceuticals, Adaptimmune Therapeutics, Nektar Therapeutics, Solid Biosciences, Vera Therapeutics, Prime Medicine, Adagene, and BioAtla. He has issued more than 140 ratings, maintaining a 50% success rate and generating an average return of 17.6% per recommendation over a one-year period, achieving a top-1,000 analyst ranking on TipRanks and notable outcomes like a +269% return on Poseida Therapeutics. Active since at least 2023 at H.C. Wainwright, details on prior firms are limited, but he holds the Chartered Financial Analyst (CFA) designation and is recognized for his quantitative research. His professional credentials include the CFA and likely FINRA securities licenses required for his role.

    Arthur He's questions to Aurinia Pharmaceuticals (AUPH) leadership

    Arthur He's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q2 2025

    Question

    Arthur He asked if Aurinia plans to present detailed data from the Aratinacept SAD study at an upcoming medical conference. He also pressed for clarity on the conditions under which the company would disclose the specific indications it is pursuing for the drug.

    Answer

    CMO Dr. Greg Keenan confirmed the data will be presented at a future medical meeting, but the specific conference has not yet been determined. CEO Peter Greenleaf explained that while the information will become public when trials are registered on clinicaltrials.gov, the company is currently withholding details for competitive reasons and has not decided on an earlier disclosure timeline.

    Ask Fintool Equity Research AI

    Arthur He's questions to NEKTAR THERAPEUTICS (NKTR) leadership

    Arthur He's questions to NEKTAR THERAPEUTICS (NKTR) leadership • Q1 2025

    Question

    Arthur He from H.C. Wainwright inquired about the potential design of a maintenance phase for the alopecia areata (AA) study, should the current Phase IIb trial prove successful. He also asked for a technical clarification on the follow-up period for patients receiving extended treatment.

    Answer

    Executive Jonathan Zalevsky explained that a future Phase III AA study would likely mirror the atopic dermatitis approach, with a higher-frequency induction period followed by a lower-frequency maintenance regimen. He clarified that all patients in the current study, including those with treatment extensions, have a 24-week off-drug follow-up period.

    Ask Fintool Equity Research AI

    Arthur He's questions to NEKTAR THERAPEUTICS (NKTR) leadership • Q3 2024

    Question

    Arthur He from H.C. Wainwright & Co. asked for clarification on the atopic dermatitis study design, specifically whether patients could receive continuous treatment during the 52-week follow-up period.

    Answer

    Chief R&D Officer Dr. Jonathan Zalevsky clarified that after the 52-week treatment period (16-week induction plus 36-week maintenance), patients will be followed for an additional 52 weeks with no further treatment. He stated the objective is to assess the potential remittive effect of REZPEG one year after therapy has concluded.

    Ask Fintool Equity Research AI

    Arthur He's questions to Adaptimmune Therapeutics (ADAP) leadership

    Arthur He's questions to Adaptimmune Therapeutics (ADAP) leadership • Q3 2024

    Question

    Arthur He asked about the real-world screening rates for MAGE-A4 and HLA compared to previous guidance and questioned the reason for lete-cel's longer duration of response (DoR) in synovial sarcoma versus afami-cel (Tecelra).

    Answer

    CEO Adrian Rawcliffe explained it's too early to confirm real-world screening rates but sees no reason to deviate from estimates derived from large clinical trial populations. Regarding the DoR, he and executive Dennis Williams noted the data is still maturing and that median DoR can be volatile with small patient numbers. They emphasized that both therapies show impressive durability and comparing across different trials and subpopulations is complex.

    Ask Fintool Equity Research AI

    Arthur He's questions to HOOKIPA Pharma (HOOK) leadership

    Arthur He's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2022

    Question

    Arthur He requested more specific details on the study initiation timeline for the randomized HB-200 trial and when initial data might be expected, and also asked for more information on the company's upcoming AACR presentation.

    Answer

    CEO Joern Aldag explained that the decision to initiate the randomized HB-200 trial is contingent on the Q2 data readout, after which more specific timelines will be provided. Chief Medical Officer Katia Schlienger confirmed that logistical preparations are complete. Regarding the AACR presentation, Mr. Aldag detailed that it will feature preclinical data on combining HB-200 with IL-2 to demonstrate enhanced therapeutic effects by driving T cells to the tumor.

    Ask Fintool Equity Research AI

    Arthur He's questions to iTeos Therapeutics (ITOS) leadership

    Arthur He's questions to iTeos Therapeutics (ITOS) leadership • Q1 2021

    Question

    Arthur He of H.C. Wainwright & Co. asked about iTeos' confidence in its adenosine antagonist for castrate-resistant prostate cancer (CRPC) as a monotherapy or doublet, given competitors' focus on triplet combinations. He also inquired about expectations for the next pipeline candidate from the adenosine pathway.

    Answer

    President and CEO Michel Detheux explained that the monotherapy approach in CRPC helps to understand the mechanism and identify patient populations, while the doublet combination with pembrolizumab offers a differentiating chemo-free regimen. He also confirmed that the research team has identified a new target in the adenosine pathway and plans to nominate a clinical candidate by the end of the year.

    Ask Fintool Equity Research AI